Guidelines from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) prioritize the use of GLP-1 RAs for patients with DKD who have cardiovascular comorbidities. This evidence concerns the gene GCG and diabetic kidney disease.